# Eupraxia Pharmaceuticals Inc.: overview EPRX · Nasdaq · CIK 1581178 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/eprx.md) · [Financials](/companies/eprx/financials.md) · [Filings](/companies/eprx/filings.md) · [Insiders](/companies/eprx/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters Not reported. ## Last five fiscal years | Line item | Unit | FY (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | [0.0](/filings/0001193125-24-083584.md) | [0.0](/filings/0001193125-25-059352.md) | [0.0](/filings/0001193125-26-104765.md) | | Gross margin | % | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.96)](/filings/0001193125-24-083584.md) | [(1.17)](/filings/0001193125-25-059352.md) | [(0.76)](/filings/0001193125-26-104765.md) | [(1.03)](/filings/0001193125-26-104765.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/eprx/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Affinity Asset Advisors, LLC](/funds/1773195.md) | 2026-06-30 | $10.9m | 1,650,000 | | Added +60,995 | | [Balyasny Asset Management L.P.](/funds/1218710.md) | 2026-06-30 | $8.9m | 1,350,015 | | Added +15 | | [Vivo Capital, LLC](/funds/1674712.md) | 2026-06-30 | $8.9m | 1,350,000 | | Unchanged | | [SCOTIA CAPITAL INC.](/funds/1335644.md) | 2026-06-30 | $8.8m | 1,343,726 | | Added +1,548 | | [PFM Health Sciences, LP](/funds/1442756.md) | 2026-06-30 | $8.0m | 1,210,661 | | Added +669,790 | | [GREAT POINT PARTNERS LLC](/funds/1281446.md) | 2026-06-30 | $7.9m | 1,200,000 | | Unchanged | | [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $6.9m | 1,046,000 | | Not compared | | [Rubric Capital Management LP](/funds/1687509.md) | 2026-06-30 | $5.7m | 867,424 | | Added +176,254 | | [Ikarian Capital, LLC](/funds/1778253.md) | 2026-06-30 | $5.4m | 809,741 | | Reduced −405,000 | | [Woodline Partners LP](/funds/1784547.md) | 2026-06-30 | $4.9m | 746,864 | | Added +306,313 | ## Recent filings [All 126 filings](/companies/eprx/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-22 | 12:50 ET | [6-K](/filings/0001171843-26-006756.md) | Report of a foreign private issuer, period 2026-10-22 | 0001171843-26-006756 | | 2026-10-15 | 14:13 ET | [6-K](/filings/0001171843-26-006648.md) | Report of a foreign private issuer, period 2026-10-15 | 0001171843-26-006648 | | 2026-10-09 | 12:27 ET | [6-K](/filings/0001171843-26-006551.md) | Report of a foreign private issuer, period 2026-10-09 | 0001171843-26-006551 | | 2026-09-30 | 12:04 ET | [6-K](/filings/0001171843-26-006307.md) | Report of a foreign private issuer, period 2026-09-30 | 0001171843-26-006307 | | 2026-09-08 | 12:05 ET | [6-K](/filings/0001171843-26-005913.md) | Report of a foreign private issuer, period 2026-09-08 | 0001171843-26-005913 | | 2026-08-13 | 12:10 ET | [6-K](/filings/0001171843-26-005479.md) | Report of a foreign private issuer, period 2026-08-13 | 0001171843-26-005479 | | 2026-08-11 | 21:24 ET | [6-K](/filings/0001193125-26-345045.md) | Report of a foreign private issuer, period 2026-08-11 | 0001193125-26-345045 | | 2026-07-15 | 17:26 ET | [6-K](/filings/0001171843-26-004676.md) | Report of a foreign private issuer, period 2026-07-15 | 0001171843-26-004676 | | 2026-07-13 | 20:15 ET | [6-K](/filings/0001171843-26-004605.md) | Report of a foreign private issuer, period 2026-07-13 | 0001171843-26-004605 | | 2026-07-07 | 20:20 ET | [6-K](/filings/0001171843-26-004516.md) | Report of a foreign private issuer, period 2026-07-07 | 0001171843-26-004516 | ## Latest annual report [Form 40-F for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-104765.md), filed Mar 13, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1581178 - Tickers: EPRX - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: A1 - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:43 ET. No prices; not investment advice.